The Aging Thymus Can Still Regenerate — Scientists Are Learning How to Unlock It

The thymus is the primary organ responsible for producing naïve T cells and establishing immune tolerance, but it begins involuting — shrinking and filling with fat — from childhood onward. For decades, this was interpreted as proof that the thymus becomes dispensable once an early-life T cell repertoire is established. This comprehensive review from Ragazzini and Bonfanti at the Francis Crick Institute and UCL systematically dismantles that assumption, synthesizing decades of experimental evidence alongside the latest single-cell and organoid technologies to argue that thymus research is entering a transformative new era.

The paradox at the heart of this review is deceptively simple: if the thymus is truly spent, why does it regenerate? Clinical observations are unambiguous — patients undergoing chemotherapy experience acute thymic atrophy followed by documented rebound hyperplasia in a high proportion of cases. Pregnancy, severe infection, and surgical sex hormone ablation all trigger thymic atrophy followed by tissue recovery. Residual thymic tissue containing immature thymocytes has been identified in aged individuals. These observations collectively indicate an endogenous regenerative mechanism that persists well into adulthood, even in an involuting organ.

The cellular basis of this regeneration centers on thymic epithelial cells (TECs), which are subdivided into cortical (cTEC) and medullary (mTEC) subtypes with distinct roles in T cell positive and negative selection. Pioneering clonal expansion assays by the Bonfanti laboratory demonstrated that both embryonic and adult rat TECs can self-renew in vitro and, critically, can reconstitute organ function when reaggregated with embryonic thymic cells and transplanted under the kidney capsule of athymic nude mice. Cells maintained this capacity across serial transplantation rounds, fulfilling the classical criteria for stem cell identity. Crucially, adult TEC-derived organoids — expanded from involuting thymus tissue — retained functional potency, directly contradicting the idea that involution exhausts the progenitor pool.

The review distinguishes sharply between embryonic/fetal thymus development and postnatal homeostasis, emphasizing that progenitor potency shifts with age and context. During fetal thymus organ culture (FTOC) experiments pioneered from E10–E14 mouse embryos, stromal and lymphoid co-development could be maintained in vitro for two weeks, validating sequential thymopoiesis as an intrinsic, culture-reproducible process. Reaggregate thymus organ cultures (RTOCs) later allowed controlled mixing of epithelial, stromal, and lymphoid cells at defined ratios, confirming TECs as the principal drivers of both positive and negative T cell selection. More recent organoid platforms further expand EpCAM+ TECs in 3D before reaggregation, extending culture fidelity.

Beyond epithelial cells, the review highlights the underappreciated roles of thymic mesenchymal and interstitial cells (TICs) and the extracellular matrix (ECM). Mesenchymal cells were identified in the 1990s as critical supporters of TEC expansion and thymus architecture, and contemporary data add endothelial cells, macrophages, B lymphocytes, and a neural plexus as additional components of the functional niche. The ECM scaffold — including fibronectin, laminins, and collagens — is increasingly recognized as an instructive rather than merely structural element, influencing TEC behavior and regeneration. The authors argue this full cellular complexity must be recapitulated to build a truly functional bioengineered thymus.

The clinical implications are substantial. The review explicitly challenges the routine surgical thymectomy performed in pediatric cardiac surgery, noting accumulating evidence that early thymic removal compromises long-term immune competence. It outlines three frontier questions: whether adult human thymus can be meaningfully rejuvenated outside of injury contexts; what minimal cellular components are sufficient to generate functional naïve T cells ex vivo; and whether next-generation humanized mouse models incorporating human thymic tissue can reliably interrogate immune tolerance and novel immunotherapies. Answers to these questions could unlock therapeutic strategies for immune aging, post-transplant reconstitution, and cancer immunotherapy.